title: Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.
abstract: BACKGROUND
  The aim of this study was to evaluate the effect of doubling the starting dose of gonadotrophins on the ovarian response in IVF patients with a low antral follicle count (AFC).
  
  
  METHODS
  Fifty-two patients with an AFC of <5 follicles of 2-5 mm diameter before starting their first IVF cycle participated in this randomized controlled trial. They were randomized by opening a sealed envelope, receiving either 150 IU (group I, n = 26) or 300 IU (group II, n = 26) of rFSH as a starting dose. The main outcome measures of the study were number of oocytes, poor response (<4 oocytes at retrieval or cancellation due to insufficient follicle growth) and ongoing pregnancy (12 weeks of gestation).
  
  
  RESULTS
  The groups were comparable regarding patient characteristics and outcome of the IVF treatment. The median number of oocytes collected was 3 for both groups (P = 0.79). The difference in the mean number of oocytes was 0.3 oocytes in favour of group I (P=0.69). Sixty-five per cent of the patients in group I experienced a poor response and 62% in group II. The ongoing pregnancy rate was 8% in group I and 4% in group II (P = 0.55).
  
  
  CONCLUSIONS
  Expected poor response patients, defined as patients with an AFC <5, are likely not to benefit from a higher starting dose of gonadotrophins in IVF.
authors.affiliation: Department of Reproductive Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. e.r.klinkert@azu.nl
authors.forename: E R
authors.initials: ER
authors.lastname: Klinkert
authors.forename: F J M
authors.initials: FJ
authors.lastname: Broekmans
authors.forename: C W N
authors.initials: CW
authors.lastname: Looman
authors.forename: J D F
authors.initials: JD
authors.lastname: Habbema
authors.forename: E R
authors.initials: ER
authors.lastname: te Velde
mesh_terms: D000328:Adult; D002452:Cell Count; D004305:Dose-Response Relationship, Drug; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D009865:Oocytes / Q000166:cytology; D006080:Ovarian Follicle / Q000000981:diagnostic imaging*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D020858:Tissue and Organ Harvesting; D017211:Treatment Failure; D014463:Ultrasonography
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone